📢 Stocks Trending NOW: #AMD #DKNG #UGRO #WVE #KOD #MARA #JBLU #BATL #EEIQ #FCHL

WVE Stock Drops 30% on INLIGHT Obesity Trial Data WVE stock plunged 30% after Wave Life Sciences released Phase 1 INLIGHT trial results. See what the data showed and why investors sold off shares.

WVE Stock Drops 30% on INLIGHT Obesity Trial Data
WVE stock plunged 30% after Wave Life Sciences released Phase 1 INLIGHT trial results. See what the data showed and why investors sold off sh...

#WVE #WaveLifeSciences #INLIGHT #ObesityTrial #BiotechStocks
https://scrollworthy.org/trending/wve-stock

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#DNN, #WVE, #UWMC, #AIRS, #RSI

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#REPL, #AVXL, #WVE, #IPI, #ULTA

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #DNN 10.7x
2. #WVE 10.0x
3. #UWMC 6.9x
4. #AIRS 6.8x
5. #RSI 5.1x

#OptionFlow #OptionsTrading #Trading

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference Wave Life Sciences (Nasdaq: WVE) announced acceptance of a late-breaking oral presentation of data from its RestorAATion-2 trial of WVE-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference, May 15-20, 2026 in Orlando.The presentation will include new data from the 400 mg multidose cohort and the 600 mg single dose cohort, and is scheduled for May 18, 2026 at 4:03 p.m. ET. The company expects regulatory feedback on a potential accelerated approval pathway for WVE-006 mid-2026 and said INLIGHT trial data for WVE-007 is expected this month.

#WVE Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

www.stocktitan.net/news/WVE/wave-life-scien...

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Wave Life Sciences (Nasdaq: WVE) reported Q4 and full-year 2025 results and a business update on Feb 26, 2026. Key points: $602.1M cash (Dec 31, 2025) with runway into 3Q 2028, advancing WVE-007 INLIGHT obesity program with 240 mg and 400 mg data due 1Q 2026, RestorAATion-2 fully enrolled through 600 mg with 400 mg multidose data in 1Q 2026, WVE-008 CTA on track for 2026, and ongoing GSK collaboration milestones.Financials: 2025 revenue $42.7M, net loss $204.4M, R&D $182.8M. Investor webcast at 8:30 a.m. ET today.

#WVE Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/WVE/wave-life-scien...

Just In: ( NASDAQ: #WVE ) WVE Price Target Alert: $30.00. Issued by H.C. Wainwright

Just In: ( NASDAQ: #WVE ) Buy Recommendation Issued On WVE By H.C. Wainwright

Leading Indicators, Thursday December 11, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Thu Dec 11th - #SRXH #WVE #PANL #MXL #PINE - More: crystalequityresearch.com/leading-indi... - #smallcap

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Wave Life Sciences (Nasdaq: WVE) priced an underwritten public offering to raise gross proceeds of approximately $350 million.The offering consists of 15,789,475 ordinary shares at $19.00 per share and, in lieu of shares to certain investors, 2,631,578 pre-funded warrants at $18.9999 each (exercise price $0.0001). Wave granted the underwriters a 30-day option to buy up to an additional 2,763,157 shares. The offering is expected to close on or about December 11, 2025, subject to customary conditions.

#WVE Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

www.stocktitan.net/news/WVE/wave-life-scien...

News; ( NASDAQ: #WVE ) Why Wave Life Sciences Stock Crushed it Again Today

Wave Life Sciences (WVE) Soars to 6-Year High on Obesity Drug Clinical Trial We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Wave Life Sciences Ltd (NASDAQ:WVE) is one of the best performers on Monday. Wave Life hit a new six-year high on Mo...

Wave Life Sciences #WVE Soars to 6-Year High on Obesity Drug Clinical Trial

uk.finance.yahoo.com/news/wave-li...

🚨 $WVE 🚨

Why is Wave Life Sciences Ltd. trending today? 🤔

#WVE #stocks #stockmarket

📢 Stocks Trending NOW: #NVDA #XCUR #VOR #WVE #PSKY #ATMC #CVS #SNTI #AZO #CPB

#GPCR #WVE #ef0a245f-cbb3-4e88-bdd9-83239da31423 #investing #Health #Care

Origin | Interest | Match

#WVE #NVO #17419064-dd44-4f18-a7fb-090774cddb43 #investing #Health #Care

Origin | Interest | Match

Most Searched, Monday December 8, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Dec 8th - #GPCR #FSLY #ABTC #TWG #JBLU #FULC #NVTS #DNN #OCUL #IRBT #BITF #PLUG #CETX #WVE #UUUU #USAR #PHR #ONDS #IDR #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

#CFLT #^DJI #^GSPC #UL #IBM #^IXIC #APD #WVE #MICC #c9ddeb14-8cdd-4408-b9c9-ddd8f1911985 #investing

Origin | Interest | Match

Wave Life Sciences Reports Encouraging Early Data for Obesity Drug WVE-007 Wave Life Sciences Ltd. (WVE) reported positive interim results from its first-in-human INLIGHT trial evaluating WVE-007 for obesity, driving shares up more tha

Wave Life Sciences ( NASDAQ: #WVE) Reports Encouraging Early Data for Obesity Drug WVE-007
prismmarketview.com/wave-life-sc...

📢 Stocks Trending NOW: #CFLT #CETX #TGL #CVNA #AVGO #CRWV #MRVL #WVE #IBM #GPCR

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 Wave Life Sciences (Nasdaq: WVE) will announce interim data from the ongoing Phase 1 INLIGHT trial of WVE-007 (INHBE) for obesity on Monday, December 8, 2025. A press release will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. Investors can access the live webcast via the company’s Investor Events page and an archived version will be available after the event.This announcement covers timing and access for interim clinical data disclosure for WVE-007; no trial results or financial metrics are included in this notice.

#WVE Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

www.stocktitan.net/news/WVE/wave-life-scien...

Leading Indicators, Thursday November 13, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Thu Nov 13th - #WVE #SVCO #REE #PENG #OMER #MOGO #LFMD #IIIV #HTLD #VUZI #FIP #DGII #CLPS #BIRD #APLT #DHX #CTEV #AAUC - More: crystalequityresearch.com/leading-indi... - #smallcap

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of

#WVE Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/WVE/wave-life-scien...

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Wave Life Sciences (NASDAQ:WVE) announced positive data from their ongoing Phase 1b/2a RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD). The study achieved significant clinical milestones, demonstrating durable production of serum AAT protein at therapeutic levels following 200 mg doses (11.9 µM total AAT, 7.2 µM M-AAT).The trial marked the first-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during an acute phase response, reaching 20.6 µM total AAT. A single 400 mg dose achieved 12.8 µM total AAT, with an ongoing multidose cohort showing potential for further increases. The data supports monthly or less frequent subcutaneous dosing, with 400 mg monthly multidose cohort data expected in Q1 2026.WVE-006, licensed to GSK, continues to demonstrate favorable safety with only mild to moderate adverse events. Wave is eligible for up to $525 million in milestones plus tiered royalties on net sales.

#WVE Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

www.stocktitan.net/news/WVE/wave-life-scien...

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration XtalPi (2228.HK) and DoveTree Medicines have announced a groundbreaking $6 billion strategic collaboration in AI-driven drug discovery. The partnership combines XtalPi's AI and robotics platform with DoveTree's biological expertise to develop novel therapeutics across multiple disease areas.Under the agreement, DoveTree receives exclusive global rights and will pay XtalPi an upfront payment of $51 million, with $49 million in near-term payments and up to $5.89 billion in milestone payments and tiered royalties. The collaboration will focus on developing first-in-class candidates in oncology, immunology, inflammation, neurology, and metabolic diseases.DoveTree, founded by renowned drug developer Dr. Gregory Verdine, brings expertise in "drugging the undruggable" targets, while XtalPi contributes its intelligent de novo drug discovery platform spanning multiple modalities including small molecules, biologics, ADCs, and molecular glues.

#ENTA #RNTX #WVE XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

www.stocktitan.net/news/ENTA/xtal-pi-and-do...

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update Wave Life Sciences (NASDAQ:WVE) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company reported a net loss of $50.5 million with cash and equivalents of $208.5 million, providing runway into 2027.Key highlights include progress in two main programs: WVE-006 for AATD (alpha-1 antitrypsin deficiency), with multi-dosing complete in first cohort (200mg) and single dosing complete in second cohort (400mg), and WVE-007 for obesity, where dosing is complete in the expanded Cohort 2. The company expects multiple data readouts in H2 2025, including RestorAATion-2 trial data in Q3 2025 and INLIGHT trial data in Q4 2025.Additionally, Wave is advancing WVE-N531 for DMD with planned NDA filing in 2026, and WVE-003 for Huntington's disease with IND submission expected in H2 2025.

#WVE Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/WVE/wave-life-scien...

Leading Indicators, Monday July 28, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend with AROON Oscillator - #OBIO #PDFS #SPWH #TCBK #UPLD #WVE #ZNTL #ACCO #BORR #DEC #EAI #FF #KRP #PRO #QUAD #RIG #SES #NESR #MFIN #LGHL #KYTX #IMMP #FATE #EVAX #DAKT #BAND #AOB - More: crystalequityresearch.com/ieading-indi... - #smallcap

Wave Life Sciences RNA Medicine Pioneer Announces Q2 2025 Earnings Date - Key Updates Expected RNA medicine developer Wave Life Sciences schedules Q2 2025 earnings call for July 30. Join live webcast at 8:30 AM ET for latest financial updates. Get Details

#WVE Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

www.stocktitan.net/news/WVE/wave-life-scien...